Table 2.
HER2(+) | HER2(-) | P value | |
---|---|---|---|
N | 9 | 36 | |
Gender (M/F) | 6/3 | 23/13 | 0.876 |
Age (mean ± SD) | 60.3 ± 10.7 | 61.6 ± 11.2 | 0.755 |
Diameter (mean ± SD) | 5.11 ± 2.89 | 5.11 ± 2.21 | 1.000 |
Diameter (<3 cm/>3 cm) | 2/7 | 10/27 | 0.768 |
Diameter (<4 cm/>4 cm) | 5/4 | 14/22 | 0.365 |
T stage (1/2/3/4) | 0/2/6/1 | 6/5/20/5 | 0.569 |
N stage (0/1-3) | 2/7 | 9/27 | 0.862 |
M stage (0/1) | 8/1 | 35/1 | 0.278 |
TNM stage (I/II/III/IV) | 1/2/5/1 | 6/11/18/1 | 0.686 |
Lauren classification (intestinal/ mixed/diffuse type) | 6/1/2 | 5/3/28 | 0.003* |
Pathologic type(adenocarcinoma /signet ring cell cancer) | 7/2 | 30/6 | 0.697 |
Differentiation degree of adenocarcinomas (poor/poor-mod/mod/mod-well)§ | 4/2/1/0 | 12/9/7/2 | 0.784 |
Overall differentiation degree (poor/poor-mod/mod/mod-well)‡ | 6/2/1/0 | 18/9/7/2 | 0.758 |
Location (cardia&fundus/cardia&body/ body/body&antrum/antrum) | 2/2/0/2/3 | 13/2/3/2/16 | 0.209 |
§poor, poorly; poor-mod, poorly to moderately; mod, moderately; mod-well, moderately to well; ‡ signet ring cell cancer was treated as poorly differentiated; * P < 0.05